MilliporeSigma’s BioContinuum Buffer Delivery Platform offers streamlined buffer management and delivers “contiGuous” bioprocessing.
MilliporeSigma’s BioContinuum Buffer Delivery Platform is a new building block in the BioContinuum Platform for next-generation bioprocessing. The new component offers a way to streamline buffer management to deliver “contiGuous” bioprocessing.
The platform is an integrated solution for more efficient buffer delivery that is tailored to provide the highest level of accuracy and precision in buffer preparation and management. The launch is timely because industry adoption of liquid buffers is expected to expand from 7% to 56% percent, according to MilliporeSigma’s internal market research.
The buffer platform is configurable and comprises four components: a selection of distinct buffer concentrates; Mobius Select single-use assemblies; an automated, accurate, and precise buffer dilution system, and tailored system services.
What the company calls “contiGuous” manufacturing goes beyond just connecting the individual unit operations; it will include the orchestration and management of all the processing steps (materials, production, testing, and analytics) with a streamlined and optimized approach.
The company has obtained certain exclusive rights to sell the buffer dilution system developed by LEWA-Nikkiso America (now a part of YMC), a manufacturer of pumps and systems for fluid metering, for customers involved in the development or production of diagnostics and biopharmaceuticals. This buffer dilution system offers the highest accuracy available for dilution of highly concentrated buffer, according to MilliporeSigma. The company supplies process buffers at a fraction of the resources and facility space, resulting in a more streamlined buffer suite and a more efficient manufacturing process, it reports.
“MilliporeSigma’s vision goes beyond continuous manufacturing and will deliver contiGuous bioprocessing-a seamless confluence of digital and intensified bioprocessing building blocks,” said Andrew Bulpin, head of process solutions at MilliporeSigma, in an April 2, 2019 company press release. “Our BioContinuum Buffer Delivery Platform is a perfect example of the high degree of connectivity that contiGuous biomanufacturing can achieve.”
Source: MilliporeSigma
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.